Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 9, 2021
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME TrialOdette S Reifsnider, Anuraag R Kansal, Christoph Wanner, et al.Eclinicalmedicine|January 10, 2022
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomesPiero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, et al.Kidney International|May 31, 2019
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamicsGert J Mayer, Christoph Wanner, Matthew R Weir, et al.Circulation. Heart Failure|June 6, 2019
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart FailureJaved Butler, Faiez Zannad, David Fitchett, et al.Journal of the American Heart Association|September 7, 2020
Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME TrialSimke W Waijer, Di Xie, Silvio E Inzucchi, et al.Journal of the American Heart Association|March 23, 2021
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME TrialJoão Pedro Ferreira, Bettina Johanna Kraus, Isabella Zwiener, et al.Journal of the American Society of Nephrology : JASN|October 14, 2018
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME TrialChristoph Wanner, Hiddo J L Heerspink, Bernard Zinman, et al.Circulation Research|July 31, 2010
Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouseMerlin C Thomas, Raelene J Pickering, Despina Tsorotes, et al.Diabetes, Obesity & Metabolism|June 22, 2017
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trialPer-Henrik Groop, Mark E Cooper, Vlado Perkovic, et al.Kidney International|November 12, 2020
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trialBettina J Kraus, Matthew R Weir, George L Bakris, et al.Pageof 3